Utang marang nilai buku: Exscientia (EXAI)

Exscientia plc (EXAI) generates revenue through the licensing of AI platforms and payments from pharmaceutical partners. The current leverage ratio on the balance sheet via GURU.Markets reflects debt load dynamics, where the value 0.07 expresses the state of the metric. The company is accelerating the development of oncology drugs while remaining in an expansion phase. The merger with Recursion Pharmaceuticals in November 2024 transformed the business into a vertically integrated industry leader.

This indicator assesses the degree of the business's dependence on borrowed funds relative to its equity. The calculation is based on total liabilities divided by the book value of assets minus debt. By analyzing the ratio of total debt to book capital, an investor determines financial stability and bankruptcy risk. The trend of this metric reflects the balance between borrowing and self-financing. For Exscientia plc (EXAI), this is critical when scaling its AI drug design platform.